Blueprint Medicines Corporation

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

by

CAMBRIDGE, Mass., June 5, 2023 /PRNewswire/ — Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective June 1, 2023, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 7,593 shares of its common stock and an aggregate of 3,796 restricted stock units (RSUs) to six new … Read more

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

by

— Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs — CAMBRIDGE, Mass., June 3, 2023 /PRNewswire/ — Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual … Read more